Skip to main content
. 2017 Dec 19;2(1):6–12. doi: 10.1002/ags3.12047

Table 2.

Anticancer drugs approved in Japan

Oral drugs
5‐FU (fluorouracil)
Tegafur
UFT (tegafur‐uracil)
5’‐DFUR (doxifluridine)
HCFU (carmofur)
S‐1 (tegafur‐gimeracil‐oteracil potassium)
UFT+LV (tegafur‐uracil+leucovorin)
Cape (capecitabine)
regorafenib
TAS‐102 (trifludine‐tipiracil hydrochloride)
Injectable drugs
5‐FU (fluorouracil)
mitomycin C
IRI (irinotecan)
5‐FU+l‐LV (fluorouracil+l‐leucovorin)
OX (oxaliplatin)
Bmab (bevacizumab)
Rmab (ramucirumab)
Cmab (cetuximab)
Pmab (panitumumab)